Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Hepatitis B virus is a leading cause of liver disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is a major global health problem. A new study has found that an antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV). The study is published in Clinical Gastroenterology and Hepatology.
[adsense:336x280:8701650588]
Pharmatech Associates and InQui Capital of Hong Kong announced the Pharmatech Connect programme, a collaboration bringing development opportunities to early stage life science technology companies in the areas of investments, market expansion and strategic alliances worldwide.
The US FDA has granted approval to Cipla's Lopinavir, Ritonavir (LPV/r) 40mg/ 10 mg oral pellets for paediatric specific treatment of HIV in infants. Cipla was working for many years in collaboration with Diana Gibb, professor of epidemiology, senior programme leader and honorary consultant paediatrician at Medical Research Council Clinical Trials Unit at UCL (University College London) towards development of this novel child-friendly formulation which has been approved by US FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. This product is a first step in making accessible more modern and appropriately formulated treatment available to the most vulnerable of HIV patients – young children.
The Indian Council on Medical Research (ICMR) and the National Institutes of Health (NIH), US, will soon begin collaborative research on ‘Prevention of Sexually Transmitted Diseases & HIV/AIDS’. The joint research programme will also have thrust on HIV and AIDS-associated co-morbidities. Under this, the focus will be on utilsation of new/enhanced therapeutics for HIV-related co-morbidities such as HCV and their impact on disease outcomes; and enhanced targeted outreach strategies for HCV testing, prevention, and treatment/care engagement; integrated approaches for addressing the complex bio-behavioral factors associated with HCV/HIV. In this regard a joint Indo-US workshop is proposed to be held in September 2015 to encourage investigators for the Indo-US collaborative projects. Under translational research, the focus will be on studies to develop and test innovative HIV prevention strategies in young populations, particularly adolescents; and also on studies to better understand linkages between reproductive health options and HIV infection in men and women.
A new research claims, the high level of zinc in the body may contribute to kidney stone formation. Zinc is key nutrient that is required for body. It may be the core by which stone formation starts, showed the results that might ultimately lead to the identification of new preventive and therapeutic approaches for urinary stone and diseases related to it. The study appeared in the scientific journal PLOS ONE.
BioCision is a leading supplier of cell cryopreservation products, systems, and solutions announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), for development of a cell thawing solution based on BioCision’s proprietary ThawSTAR technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.
A master clock in the brain, sends out signals that synchronize the molecular clocks ticking away in almost every cell and tissue of the body. Disruption of the clock linked with a variety of health problems, including diabetes, heart disease, and cancer.
Mylan N.V., a global pharmaceutical company, launched guanfacine extended-release tablets, 1 mg, 2 mg, 3 mg, and 4 mg, which is the generic version of Shire's Intuniv tablets in US markets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications.The company received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.
AstraZeneca Pharma India Limited and Dr. Reddy’s Laboratories Ltd. Collaborate to marketing for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and marketed in the Indian market.
OPTM Healthcare, with its ever evolving streak of innovating absolutely natural treatments with 100% recovery, has devised a remarkable alternative to treat osteoarthritis with phytomedicines. Its team of professional physicians has scientifically developed plant-originated Indian herbal medicines, known as phytomedicines, to use as an excellent cure for this disease along with many others.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
